Only Benzoyl Peroxide Wash to Utilize MICROSPONGE(R) Delivery System
CARLSBAD, Calif., Jan. 14 /PRNewswire/ -- SkinMedica, Inc. today announced the launch of NeoBenz Micro Wash, the only prescription benzoyl peroxide wash product formulated with the MICROSPONGE(R) delivery system, for the treatment of mild to moderate acne vulgaris. NeoBenz Micro Wash contains 7% benzoyl peroxide.
NeoBenz Micro Wash follows on the success of NeoBenz Micro Cream and NeoBenz Micro SD which launched in January of 2006 and January of 2007, respectively. Within one year of launch, NeoBenz Micro Cream became the most-prescribed benzoyl peroxide cream or gel by dermatologists.
"NeoBenz Micro Wash is a cosmetically elegant, easy to lather formulation and the only benzoyl peroxide wash medication to utilize the benefits of the MICROSPONGE(R) delivery system. The benzoyl peroxide entrapped microspheres have been shown to remain on the skin post-rinse. This slow release of benzoyl peroxide provides a lower incidence of irritation which may result in improved compliance and better therapeutic results," said Rex Bright, president at SkinMedica.
The clinical benefits of NeoBenz Micro Wash were evaluated in a randomized, investigator-blinded trial comparing the tolerability of NeoBenz Micro Wash with a non-medicated gentle cleansing wash. Forty-six (46) mild to moderate acne patients were assigned to receive once daily treatment with one of the washes for 21 days. Results showed that both groups exhibited excellent local cutaneous tolerability and mean scores measurable at baseline were minimal and improved during the course of the study. There were no statistical differences between the two regimens for erythema, dryness/scaling, burning/stinging or pruritus.
"These data demonstrate a low incidence of irritation for NeoBenz Micro Wash that was on par with the gentle cleansing wash," said investigator Nathan Trookman, MD, Colorado Springs Dermatology Clinic, Colorado Springs, CO.
NeoBenz Micro Wash, NeoBenz Micro Cream and NeoBenz Micro SD are the only prescription products in which the MICROSPONGE(R) delivery system is used in combination with this proven antibacterial acne-fighter. Benzoyl peroxide, entrapped in these porous microspheres, is gradually released onto the skin throughout the day. This gradual, more controlled release is designed to reduce irritation to the skin while the active agent fights existing acne and helps to prevent new pimples from forming.
Acne is a disease for which 5.6 million U.S. patients were diagnosed in the past year. Of these, 2.9 million (52%) were diagnosed by dermatologists. The NeoBenz Micro family of products helps to stop acne and prevent new acne from forming via a multi-pronged approach. The active ingredient, benzoyl peroxide, is released gradually throughout the day to kill the P. acnes bacteria, reduce inflammation, open plugged follicles and slow formation of whiteheads, blackheads and inflamed pimples.
The NeoBenz Micro family of products can also be used in combination therapy (i.e. with topical retinoids or antibiotics) to help increase overall efficacy of treatment, and may also help prevent antibiotic resistance when used with antibiotic treatments.
As with all benzoyl peroxide products, NeoBenz Micro Wash, NeoBenz Micro Cream and NeoBenz Micro SD should not be used in patients who have shown hypersensitivity to benzoyl peroxide or to any of the other ingredients. Allergic contact dermatitis and dryness have been reported with topical benzoyl peroxide therapy.
MICROSPONGE(R) is a registered trademark of AMCOL International Corporation.
SkinMedica, Inc. is focused on developing, acquiring and commercializing products that treat dermatologic conditions and improve the appearance of skin. We market and sell primarily to dermatologists, both prescription pharmaceutical products and physician-dispensed, non-prescription skin care products. SkinMedica's pharmaceutical products include Desonate(R) (desonide) Gel 0.05% for the treatment of mild to moderate atopic dermatitis; VANIQA(R) (eflornithine hydrochloride) Cream, 13.9%, the only FDA-approved prescription product for the treatment of unwanted facial hair in women; NeoBenz(R) Micro Cream, NeoBenz(R) Micro SD and NeoBenz(R) Micro Wash, all of which incorporate the patented gradual-release MICROSPONGE(R) delivery system of benzoyl peroxide, for the treatment of acne; and EpiQuin(R) Micro Cream (4% hydroquinone) for the treatment of melasma and postinflammatory hyperpigmentation. The company's full line of aesthetic products -- which began with TNS Recovery Complex(R) as the inspiration for its comprehensive line -- are designed to enhance skin appearance, reduce signs of aging and provide other skin care benefits. SkinMedica is based in Carlsbad, California. For more information, visit: www.skinmedica.com.
Desonate(R), EpiQuin(R) Micro, NeoBenz(R) Micro, SkinMedica(R), TNS Recovery Complex(R) and VANIQA(R) are registered trademarks of SkinMedica, Inc.
CONTACT: Wendy Johnson, Senior Product Manager, Pharmaceuticals of
SkinMedica, Inc., +1-760-448-3651, email@example.com
Web site: http://www.skinmedica.com/